Press Releases
GI Dynamics Announces EndoBarrier Data to be Presented at Digestive Disease Week
BOSTON and SYDNEY — 4 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced that new EndoBarrier data will be presented at Digestive Disease Week®...
read moreGI Dynamics Selects Allenby Capital to Explore AIM Listing Option
BOSTON and SYDNEY — 3 May 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces Allenby Capital Limited’s engagement to explore options for seeking...
read moreGI Dynamics to Release 2016 Annual Report and Host Webcast for Year Ending 31 December 2016
BOSTON and SYDNEY – 23 March 2017 – GI Dynamics, Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe and the Middle East for patients with type 2 diabetes and obesity, announced that it will release its 2016 Annual Report on Form 10K on or before 31 March EDT |...
read moreGI Dynamics Announces Scientific Advisory Board Members to Further Scientific Understanding of EndoBarrier
BOSTON and SYDNEY — 13 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced additional members of the GI Dynamics Scientific Advisory Board...
read moreGI Dynamics Announces New Scientific Advisory Board and Board’s First Two Members
BOSTON and SYDNEY — 7 March 2017 — GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announced the creation of the GI Dynamics Scientific Advisory Board (SAB). The...
read moreEndoBarrier® Study in Morbidly Obese Adolescents Completes Enrollment
First study of EndoBarrier in adolescents completed at University Children’s Hospital (UCH) in Ljubljana, Slovenia Preliminary data show BMI reduced by 10 percent Acceptable safety profile and improvement in metabolic parameters BOSTON and SYDNEY — 16 February 2017 — GI Dynamics, Inc. (ASX:GID), a...
read moreEndoBarrier® Receives German NUB Reimbursement Status 1 for Type 2 Diabetes and Obesity Therapy
FOR IMMEDIATE RELEASE BOSTON and SYDNEY — 1 February 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier in Europe for patients with type 2 diabetes and obesity, announces that InEk, the German Institute for the Hospital Remuneration System, has...
read moreGI Dynamics, Inc. Provides 2017 Business Outlook and 2016 Review
BOSTON and SYDNEY — 11 January 2017 — GI Dynamics, Inc., (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe for patients with type 2 diabetes and obesity, today released a 2017 business outlook and recap of 2016 accomplishments. 2017 marks the first full calendar...
read moreGI Dynamics, Inc. Appoints Oern R. Stuge, MD, MBA, Amid Change to Company’s Board of Directors
BOSTON and SYDNEY — 5 January 2017 — GI Dynamics, Inc. (ASX:GID), a medical device company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity, today announced the appointment of veteran medical device executive Oern Stuge, M.D., MBA,...
read moreGI Dynamics, Inc. Announces Completion of A $1.5million Private Placement and Launch of Security Purchase Plan
GI Dynamics®, (ASX:GID) a medical technology company that has developed an innovative device to improve outcomes for patients diagnosed with type 2 diabetes and obesity is pleased to announce that it has received commitments for a private placement of 69,865,000 fully paid CHESS Depositary...
read more